On 27 October 2021, AIM (a Blue Matter company) hosted a webinar panel discussion that addressed the key supply chain aspects associated with launching a new pharmaceutical or biotech therapy in Europe.
Our panel of experts included:
- Pim Van Der Aar, Co-Founder & Managing Director, AIM (Moderator)
- Christian Ellereit, Head of Finance, Europe, Travere Therapeutics
- Ronald van Zitteren, Principal, AIM
- Joop Wijdeven, Associate, AIM
The panelists covered supply chain key success factors, best practices, and common pitfalls and mistakes. They also discussed key licensing and legal requirements, as well as the main steps involved in designing and implementing a life science supply chain in Europe. This paper provides a written summary of the webinar.